Skip to content
DataLookout
Menu

NCT07916389

Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Rate of Complete Tumor Response (CTR) among patients in Strata A, B, and C
Timeframe: approximately 4 months after enrollment
Rate of safe surgical resection among patients in Strata A, B, and C
Timeframe: Up to 72 hours after surgery

Secondary (4)

Event free survival (EFS)
Overall survival (OS)
Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: BSID-4
Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: NIH Baby Toolbox

Arms and interventions

Stratum AExperimental

* Neoadjuvant Treatment: Participants with ALK fusions will receive neoadjuvant treatment (4 Courses) with alectinib. * Surgery * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).

Stratum BExperimental

* Neoadjuvant Treatment: Participants with NTRK 1/2/3 or ROS1 fusions will receive neoadjuvant (4 Courses) treatment with entrectinib. * Surgery * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).

Stratum CExperimental

* Neoadjuvant Treatment: Participants no RTK fusion or RTK fusions other than ALK, ROS1 or NTRK1/2/3 (including MET fusion) will receive neoadjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses). * Surgery * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).

Stratum DExperimental

Participants who have no measurable residual disease at the time of enrollment. * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).

Drugs: Alectinib, Entrectinib, Cyclophosphamide, Etoposide, Carboplatin

Procedures: Surgery

Biologicals: Filgrastim, Pegfilgrastim

Sites

1 site in 1 country

  • St. Jude Children's Research HospitalMemphis, Tennessee, United States